Dr. Reddy's Lab Q2 income at Rs. 494 cr.

Aided by a steep rise in international sales, Dr.Reddy's Laboratories has reported a higher total income of Rs.494.30 crores against Rs. 164.6 crores and a net profit of Rs. 143 crores against Rs. 29.47 crores for the second quarter ended September 30, 2001.

The board of directors have declared a special interim dividend of Rs.5 for every equity share of Rs.5 face value.

A press release said international sales went up to Rs. 297.8 crores from Rs. 94.9 crores, contributing nearly two thirds of total turnover. Sales of Fluoxetine 40 mg capsules were Rs.163.9 crores, constituting 35 per cent of total sales.

In the process, U. S. emerged as the single largest market accounting for 43 per cent of turnover. There was also a marked shift in business mix with generics accounting for 39 per cent, and branded formulations at 35 per cent. Earnings per share for the quarter was Rs. 18.98, considering the stock split.

Send this article to Friends by E-Mail

Section  : Business
Previous : New phase of ILO programme to begin soon
Next     : Lower profit for Titan Industries